MicroRNA targets have shown enormous potential for understanding, diagnosing, and even treating the world's most prevalent diseases including cancer, heart disease, Alzheimer's, diabetes and many more. Unfortunately, miRNAs are particularly challenging to quantify due to their small size, sequence homology, and wide range of abundance. As such, miRNA profiling is either expensive or low-throughput using today's state-of-the art technologies. To overcome these limitations, a new multiplexing technology built on encoded hydrogel microparticles and a custom microRNA labeling scheme will be scaled up, automated, and validated. This project could have implications in cancer research, drug discovery, and cancer diagnostics.

Public Health Relevance

The aim of this project is to develop a technology capable of profiling across all human microRNA in a manner that is accurate, rapid, and inexpensive. This tool will be enabling for cancer research, drug discovery, and cancer diagnostics.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
2R44CA141980-02A1
Application #
8126610
Study Section
Special Emphasis Panel (ZRG1-IMST-J (15))
Program Officer
Weber, Patricia A
Project Start
2009-09-01
Project End
2013-07-31
Budget Start
2011-08-01
Budget End
2012-07-31
Support Year
2
Fiscal Year
2011
Total Cost
$1,060,790
Indirect Cost
Name
Firefly Bioworks, Inc.
Department
Type
DUNS #
828298195
City
Cambridge
State
MA
Country
United States
Zip Code
02139